Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14976692 | 0.90 | TBK1 (0.46) | TBK1 | |
| SCHEMBL31402961 | 0.90 | IKBKB (0.40) | ACACBTBK1IP6K1CHEK1CHRNB2 | |
| SCHEMBL31403060 | 0.82 | RORC (0.40) | ACACBTBK1HPGDJAK2 | |
| SCHEMBL29818537 | 0.81 | ACACB (0.41) | ACACBTBK1IP6K1MALT1CHRM4 | |
| SCHEMBL20265237 | 0.81 | ACACB (0.41) | ACACBTBK1IP6K1MALT1CHRM4 | |
| SCHEMBL323094 | 0.76 | GAA (0.40) | CHEK1MEN1POLBHPGDKMT2A | |
| SCHEMBL31294273 | 0.76 | GAA (0.40) | CHEK1MEN1POLBHPGDKMT2A | |
| SCHEMBL22906900 | 0.76 | CTSL (0.40) | ACACB | |
| SCHEMBL22906969 | 0.76 | CTSL (0.40) | ACACB | |
| SCHEMBL29547503 | 0.76 | CTSL (0.40) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| WO-2023205507-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, SHBG, NR5A1 | ACACB 922/4885TBK1 4416/4885IP6K1 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.